Everolimus, a derivative of rapamycin that inhibits the mammalian target of rapamycin (mTOR) threonine kinase, has been approved as a second- and third-line therapy for patients with advanced RCC [65,66,67]. This evidence concerns the gene MTOR and renal cell carcinoma.